Thrombopoietin Receptor Agonists for Acquired Thrombocytopenia Following Anti-CD19 CAR-T-Cell Therapy: A Case Report

The authors report on a 66-year-old woman with relapsed/refractory diffuse large B-cell lymphoma who received anti-CD19 CAR-T-cells and exhibited a grade 3 anemia and a grade 4 thrombocytopenia 3 months after adoptive cell transfer. The authors treated with romiplostim, a thrombopoietin receptor-agonist, and suggest that its use could represent a novel strategy for managing CAR-T-cell-related hematotoxicity, although further controlled clinical studies are required.